-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30

Benzinga·09/09/2026 13:28:37
語音播報
RBC Capital analyst Luca Issi maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $35 to $30.